Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.…
Kyntra Bio (KYNB) Stock Fair Value Moves Lower After Analysts Reset Targets
Kyntra Bio (NASDAQ: KYNB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 34 employees.
The shares were at 1.560 USD on 20 November 2026, down 85.9% over 52 weeks. Its 52-week range is 1.556 USD to 11.19 USD, and it trades at the bottom of that range.
Its market capitalisation is 6.32M USD.
Kyntra Bio reports revenue up 63.8% year over year.
It holds more cash than debt, a net cash position of 40.29M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. The next earnings report is expected on 22 March 2027.